Prediction: 2 Stocks That'll Be Worth More Than Palantir 3 Years From Now
Palantir's valuation has risen much higher than Nvidia's.
ASML and AMD just have to continue being themselves to be larger than Palantir if a correction comes.
10 stocks we like better than Palantir Technologies ›
Palantir (NASDAQ: PLTR) is one of the hottest stocks in the market. It has delivered explosive returns for shareholders this year and is rapidly growing from a business standpoint, too.
There's nothing to dislike about Palantir's business from an investing standpoint (you may have qualms about what its software is used for in government, but that's beside the point), but there is a lot to dislike about the stock.
Alongside Palantir's rapid rise has been a massive expansion in valuation, and it has become the most expensive stock on the market. I think that this is unsustainable and could lead to some lackluster stock performance over the next few years.
Although Palantir has a market cap of over $425 billion, I think ASML (NASDAQ: ASML) and AMD (NASDAQ: AMD) could surpass it over the next three years, despite each being worth around $275 billion.
The case against Palantir
As mentioned above, Palantir's business is phenomenal. Its software is becoming the building blocks for deploying AI in business and government, and it has the growth to show for it. In the second quarter, Palantir's revenue rose 48% year over year to more than $1 billion. That blew away expectations and showcases the unstoppable demand Palantir is experiencing.
The problem is that the growth rate is already baked into the stock.
One of the premier AI stocks over the past few years has been Nvidia. Nvidia posted growth rates of more than 200% during its run, yet never traded for more than 46 times sales or 51 times forward earnings. Palantir has far exceeded those levels despite much slower growth.
Let's break down what growth it would take for Palantir to trade at a reasonable level. If Palantir can sustain a 50% revenue growth rate over the next three years, it would increase its revenue from today's $3.44 billion total to $11.6 billion. If we give Palantir a 30% profit margin (its profit margin was 22% over the past 12 months), that would indicate Palantir would generate $3.5 billion in profits.
At today's $425 billion market cap, that would still price Palantir's stock at 122 times three-year forward earnings. This showcases how expensive Palantir's stock is, and indicates it could be ripe for a pullback.
As a result, I think it's possible that ASML and AMD could be larger than Palantir in three years by doing nothing different.
ASML and AMD don't have to do anything special to be worth more than Palantir
Both ASML and AMD are reasonably priced for their current business, and each is expected to put up respectable growth figures over the next few years, although still far slower than Palantir.
Using Nvidia's max valuation of about 50 times forward earnings as the high point for Palantir's earnings in three years ($3.5 billion), that would indicate the stock should be worth around $175 billion. As mentioned before, Palantir trades at around a $425 billion market cap right now, so this would indicate a substantial drop.
Both ASML and AMD are valued at around $275 billion, so Palantir's potential drop would cause these two to be worth more.
Palantir is an incredibly overvalued stock, but it has a strong and devoted following, and it may continue to defy traditional valuation metrics, similar to Tesla. Investors are more than capable of holding onto Palantir stock at elevated prices, so the correction to its price may never come, despite all factors indicating that it should.
I still think AMD and ASML will (and should) be valued higher than Palantir's stock, but investors will have to wait and find out if that turns out to be true.
Should you buy stock in Palantir Technologies right now?
Before you buy stock in Palantir Technologies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!*
Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of August 4, 2025
Keithen Drury has positions in ASML, Nvidia, and Tesla. The Motley Fool has positions in and recommends ASML, Advanced Micro Devices, Nvidia, Palantir Technologies, and Tesla. The Motley Fool has a disclosure policy.
Prediction: 2 Stocks That'll Be Worth More Than Palantir 3 Years From Now was originally published by The Motley Fool
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Key Points Hims & Hers Health continues to post robust growth. Shares sold off, however, after revenue missed analyst expectations. The stock is still reasonably valued given its growth prospects. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS) is one of the most volatile stocks on the market at the moment, prone to big swings in either direction. This is true even intraday, as the stock plunged following the company's second-quarter results, only to rally back, only to plunge again. As of this writing, the stock is still trading up more than 130% this year. Let's take a closer look at the most recent earnings results for this telehealth company focused on providing accessible and affordable healthcare solutions for various health and wellness needs, and its prospects. Who knows, you might want to jump in on this somewhat volatile growth stock. Hims saw strong revenue growth in Q2 Hims & Hers continued to deliver outstanding revenue growth in Q2, with sales climbing 73% year over year to $544.8 million. That was toward the high end of its forecast for revenue of $530 million to $550 million, but it missed analyst expectations for revenue of $552 million. Monthly online revenue per subscriber jumped 30% to $74 per month, while the number of subscribers climbed 31% to nearly 2.44 million. The company said that the number of subscribers in both oral weight loss and dermatology grew more than 55% in the quarter. Customers using at least one personalized subscription increased by 89% to 1.5 million, representing more than 60% of the Hims & Hers subscriber base. It said that 70% of new patients who join the platform use a personalized treatment plan, and that the number of subscribers using a personalized treatment plan to treat multiple conditions skyrocketed 170% to more than 500,000. Revenue from GLP-1 weight loss drugs fell from $230 million in Q1 to $190 million in Q2, after Novo Nordisk ended a partnership with the telehealth company. Nonetheless, it still expects to generate $725 million of revenue this year from weight loss drugs, led by oral weight loss products and personalized doses. Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending jumped 50% to nearly $218 million. Marketing expenses took up 40% of revenue in the quarter, though that was down from 46% a year ago, so the company continues to see leverage in this area despite the increased spending. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) surged to $82.2 million from $39.3 million a year ago. Adjusted earnings per share (EPS) came in at $0.17, topping the $0.15 analyst consensus as compiled by LSEG. Metric Q1 Results Growth (YOY) Revenue $544.8 million 73% Monthly online revenue per subscriber $74 30% Subscribers 2.44 million 31% Adjusted EBITDA $82.2 million 109% Adjusted EPS $0.17 183% Marketing expense $231 million 77% Marketing as % of revenue 40% (600 basis points) Gross margin 76% (500 basis points) Data source: Hims & Hers Health. YOY = year over year. Looking ahead, Hims & Hers maintained its forecast for 2025 revenue to be between $2.3 billion and $2.4 billion, equal to growth of 56% to 63%. It also kept its adjusted EBITDA guidance of $295 million to $335 million. For Q3, it projected revenue of between $570 million and $590 million, and adjusted EBITDA of $60 million to $70 million. The company is starting to look toward international expansion to bolster growth. It will begin by focusing on Canada next year, while its acquisition of Zava in July will help it expand into Europe. It also anticipates entering the Latin American and Asian markets in the coming years. Hims & Hers also continues to expand into new areas. It will launch hormonal health soon, starting with lab testing. The company believes this will help it reach its targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA in 2030. Is the stock a buy? Hims & Hers continues to be a growth engine. Even though there's been some disruption from its spat with Novo Nordisk, it is still seeing strong growth across different health categories. With the company moving into new areas, like hormonal health and longevity, and looking to expand internationally, it has a lot of growth opportunities ahead. Meanwhile, with the majority of its subscribers on personalized treatment plans, it has a pretty sticky user base. From a valuation standpoint, the stock trades at a forward price-to-earnings (P/E) ratio of around 55 based on the analyst consensus for 2025. But its forward price/earnings-to-growth ratio (PEG) is under 0.6, and stocks with PEG ratios below 1 are usually considered undervalued. Given that it operates a subscription business with high gross margins, you can also look at the stock from a price-to-sales perspective; on that front, it trades at a multiple of 5.5 times 2025 analyst estimates. Overall, I'd say, based on the type of business the company is in, that it's still reasonably priced. However, it's still a volatile stock that carries some risk depending on what happens in the weight loss segment. Still, I really like its international opportunity, and think Hims & Hers Health could have solid long-term upside from here. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills? was originally published by The Motley Fool 登入存取你的投資組合
Yahoo
5 minutes ago
- Yahoo
TBC Bank Group Second Quarter 2025 Earnings: EPS: GEL6.14 (vs GEL5.94 in 2Q 2024)
Explore TBC Bank Group's Fair Values from the Community and select yours TBC Bank Group (LON:TBCG) Second Quarter 2025 Results Key Financial Results Revenue: GEL719.5m (up 11% from 2Q 2024). Net income: GEL340.9m (up 5.0% from 2Q 2024). Profit margin: 47% (down from 50% in 2Q 2024). The decrease in margin was driven by higher expenses. EPS: GEL6.14 (up from GEL5.94 in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period TBC Bank Group Earnings Insights Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Banks industry in the United Kingdom. Performance of the British Banks industry. The company's shares are up 1.5% from a week ago. Balance Sheet Analysis While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on TBC Bank Group's balance sheet. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
Those who invested in PPC (JSE:PPC) five years ago are up 641%
Explore PPC's Fair Values from the Community and select yours For many, the main point of investing in the stock market is to achieve spectacular returns. And highest quality companies can see their share prices grow by huge amounts. To wit, the PPC Ltd (JSE:PPC) share price has soared 535% over five years. If that doesn't get you thinking about long term investing, we don't know what will. Meanwhile the share price is 2.4% higher than it was a week ago. We love happy stories like this one. The company should be really proud of that performance! So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During the last half decade, PPC became profitable. That kind of transition can be an inflection point that justifies a strong share price gain, just as we have seen here. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). It is of course excellent to see how PPC has grown profits over the years, but the future is more important for shareholders. If you are thinking of buying or selling PPC stock, you should check out this FREE detailed report on its balance sheet. What About Dividends? It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. We note that for PPC the TSR over the last 5 years was 641%, which is better than the share price return mentioned above. This is largely a result of its dividend payments! A Different Perspective It's nice to see that PPC shareholders have received a total shareholder return of 44% over the last year. That's including the dividend. Having said that, the five-year TSR of 49% a year, is even better. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with PPC , and understanding them should be part of your investment process. We will like PPC better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on South African exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
